Does the media refer more to CERT or NRC?

In the previous week, Certara had 3 more articles in the media than National Research. MarketBeat recorded 6 mentions for Certara and 3 mentions for National Research. Certara's average media sentiment score of 0.69 beat National Research's score of 0.55 indicating that Certara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Certara 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Research 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NRC or GDRX?

GoodRx has higher revenue and earnings than National Research. National Research is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio National Research $140.00M 3.31 $11.60M $0.25 81.40 GoodRx $796.85M 1.41 $30.44M $0.04 82.00

Does the media favor NRC or GDRX?

In the previous week, National Research had 2 more articles in the media than GoodRx. MarketBeat recorded 3 mentions for National Research and 1 mentions for GoodRx. National Research's average media sentiment score of 0.55 beat GoodRx's score of 0.50 indicating that National Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRC or TDOC?

In the previous week, Teladoc Health had 1 more articles in the media than National Research. MarketBeat recorded 4 mentions for Teladoc Health and 3 mentions for National Research. Teladoc Health's average media sentiment score of 0.66 beat National Research's score of 0.55 indicating that Teladoc Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teladoc Health 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRC or HSTM?

In the previous week, National Research and National Research both had 3 articles in the media. HealthStream's average media sentiment score of 1.27 beat National Research's score of 0.55 indicating that HealthStream is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthStream 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

National Research (NRC) Competitors

$20.35 -0.97 (-4.55%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$20.40 +0.05 (+0.25%)

As of 10/2/2026 07:30 PM Eastern

Compare

NRC vs. CERT, GDRX, TDOC, HSTM, and SOPH

Should you buy National Research stock or one of its competitors? National Research's main competitors and comparable companies include Certara (CERT), GoodRx (GDRX), Teladoc Health (TDOC), HealthStream (HSTM), and SOPHiA GENETICS (SOPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does National Research compare to Certara?

Certara (NASDAQ:CERT) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Certara has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, National Research has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Certara had 3 more articles in the media than National Research. MarketBeat recorded 6 mentions for Certara and 3 mentions for National Research. Certara's average media sentiment score of 0.69 beat National Research's score of 0.55 indicating that Certara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Certara	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Research	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Certara presently has a consensus target price of $8.45, indicating a potential downside of 9.72%. National Research has a consensus target price of $26.00, indicating a potential upside of 27.76%. Given National Research's stronger consensus rating and higher probable upside, analysts clearly believe National Research is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

74.0% of Certara shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 1.1% of Certara shares are held by insiders. Comparatively, 9.2% of National Research shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

National Research has lower revenue, but higher earnings than Certara. Certara is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84M	3.41	-$1.60M	-$0.45	N/A
National Research	$140.00M	3.31	$11.60M	$0.25	81.40

National Research has a net margin of 4.18% compared to Certara's net margin of -16.75%. National Research's return on equity of 164.26% beat Certara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Certara	-16.75%	3.86%	2.65%
National Research	4.18%	164.26%	14.67%

Summary

National Research beats Certara on 9 of the 17 factors compared between the two stocks.

How does National Research compare to GoodRx?

National Research (NASDAQ:NRC) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

47.3% of National Research shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 9.2% of National Research shares are owned by insiders. Comparatively, 5.9% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, National Research had 2 more articles in the media than GoodRx. MarketBeat recorded 3 mentions for National Research and 1 mentions for GoodRx. National Research's average media sentiment score of 0.55 beat GoodRx's score of 0.50 indicating that National Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

National Research presently has a consensus price target of $26.00, indicating a potential upside of 27.76%. GoodRx has a consensus price target of $4.23, indicating a potential upside of 28.88%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

GoodRx has higher revenue and earnings than National Research. National Research is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$140.00M	3.31	$11.60M	$0.25	81.40
GoodRx	$796.85M	1.41	$30.44M	$0.04	82.00

National Research has a net margin of 4.18% compared to GoodRx's net margin of 2.07%. National Research's return on equity of 164.26% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
GoodRx	2.07%	7.22%	2.53%

National Research has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Summary

National Research beats GoodRx on 9 of the 16 factors compared between the two stocks.

How does National Research compare to Teladoc Health?

National Research (NASDAQ:NRC) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

National Research has a net margin of 4.18% compared to Teladoc Health's net margin of -7.13%. National Research's return on equity of 164.26% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
Teladoc Health	-7.13%	-12.15%	-5.83%

National Research presently has a consensus target price of $26.00, indicating a potential upside of 27.76%. Teladoc Health has a consensus target price of $7.54, indicating a potential upside of 36.12%. Given Teladoc Health's higher possible upside, analysts clearly believe Teladoc Health is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Teladoc Health had 1 more articles in the media than National Research. MarketBeat recorded 4 mentions for Teladoc Health and 3 mentions for National Research. Teladoc Health's average media sentiment score of 0.66 beat National Research's score of 0.55 indicating that Teladoc Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teladoc Health	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.3% of National Research shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 9.2% of National Research shares are held by company insiders. Comparatively, 0.7% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

National Research has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

National Research has higher earnings, but lower revenue than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$140.00M	3.31	$11.60M	$0.25	81.40
Teladoc Health	$2.53B	0.40	-$200.32M	-$0.99	N/A

Summary

National Research beats Teladoc Health on 9 of the 16 factors compared between the two stocks.

How does National Research compare to HealthStream?

National Research (NASDAQ:NRC) and HealthStream (NASDAQ:HSTM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

National Research pays an annual dividend of $0.64 per share and has a dividend yield of 3.1%. HealthStream pays an annual dividend of $0.14 per share and has a dividend yield of 0.5%. National Research pays out 256.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. HealthStream pays out 19.4% of its earnings in the form of a dividend. HealthStream has raised its dividend for 2 consecutive years.

In the previous week, National Research and National Research both had 3 articles in the media. HealthStream's average media sentiment score of 1.27 beat National Research's score of 0.55 indicating that HealthStream is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthStream	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

National Research has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

National Research currently has a consensus price target of $26.00, suggesting a potential upside of 27.76%. HealthStream has a consensus price target of $27.00, suggesting a potential downside of 12.39%. Given National Research's stronger consensus rating and higher possible upside, equities analysts clearly believe National Research is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

HealthStream has a net margin of 6.60% compared to National Research's net margin of 4.18%. National Research's return on equity of 164.26% beat HealthStream's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
HealthStream	6.60%	6.81%	4.64%

47.3% of National Research shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 9.2% of National Research shares are held by company insiders. Comparatively, 20.4% of HealthStream shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

HealthStream has higher revenue and earnings than National Research. HealthStream is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$140.00M	3.31	$11.60M	$0.25	81.40
HealthStream	$304.06M	2.96	$18.34M	$0.72	42.81

Summary

HealthStream beats National Research on 10 of the 18 factors compared between the two stocks.

How does National Research compare to SOPHiA GENETICS?

National Research (NASDAQ:NRC) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

National Research has a net margin of 4.18% compared to SOPHiA GENETICS's net margin of -93.86%. National Research's return on equity of 164.26% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

In the previous week, National Research had 3 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 3 mentions for National Research and 0 mentions for SOPHiA GENETICS. National Research's average media sentiment score of 0.55 beat SOPHiA GENETICS's score of 0.00 indicating that National Research is being referred to more favorably in the media.

Company	Overall Sentiment
National Research	Positive
SOPHiA GENETICS	Neutral

National Research has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

National Research has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$140.00M	3.31	$11.60M	$0.25	81.40
SOPHiA GENETICS	$77.27M	8.76	-$79M	-$1.15	N/A

47.3% of National Research shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

National Research presently has a consensus price target of $26.00, indicating a potential upside of 27.76%. SOPHiA GENETICS has a consensus price target of $10.00, indicating a potential upside of 23.92%. Given National Research's stronger consensus rating and higher possible upside, analysts clearly believe National Research is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

National Research beats SOPHiA GENETICS on 13 of the 16 factors compared between the two stocks.

Get National Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRC vs. The Competition

Export

Metric	National Research	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$484.95M	$1.78B	$7.14B	$13.17B
Dividend Yield	3.02%	3.95%	2.53%	16.77%
P/E Ratio	81.40	21.02	274.33	26.04
Price / Sales	3.31	87.64	616.11	85.50
Price / Cash	16.96	31.91	77.60	51.75
Price / Book	32.82	6.16	10.93	6.31
Net Income	$11.60M	-$18.66M	$3.51B	$362.16M
7 Day Performance	3.99%	-2.24%	-2.02%	-1.67%
1 Month Performance	-4.24%	-1.62%	-6.17%	-4.51%
1 Year Performance	66.67%	-21.59%	7.45%	2.03%

National Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRC National Research	2.8308 of 5 stars	$20.35 -4.5%	$26.00 +27.8%	+63.3%	$484.95M	$140.00M	81.40	357	News Coverage
CERT Certara	1.7897 of 5 stars	$8.83 +3.6%	$8.28 -6.3%	-31.2%	$1.30B	$418.84M	N/A	1,576	Analyst Upgrade
GDRX GoodRx	3.8454 of 5 stars	$3.44 +1.5%	$4.23 +22.9%	-26.9%	$1.16B	$796.85M	86.02	697	News Coverage
TDOC Teladoc Health	3.3129 of 5 stars	$6.34 +1.1%	$7.54 +18.8%	-34.4%	$1.14B	$2.53B	N/A	5,600
HSTM HealthStream	2.4011 of 5 stars	$29.01 -0.2%	$27.00 -6.9%	+12.0%	$849.58M	$304.06M	40.29	1,160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRC) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

National Research (NRC) Competitors

NRC vs. CERT, GDRX, TDOC, HSTM, and SOPH

How does National Research compare to Certara?

Summary

How does National Research compare to GoodRx?

Summary

How does National Research compare to Teladoc Health?

Summary

How does National Research compare to HealthStream?

Summary

How does National Research compare to SOPHiA GENETICS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRC vs. The Competition

National Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

National Research (NRC) Competitors

NRC vs. CERT, GDRX, TDOC, HSTM, and SOPH

How does National Research compare to Certara?

Which has more volatility & risk, CERT or NRC?

Does the media refer more to CERT or NRC?

Do analysts rate CERT or NRC?

Do institutionals & insiders believe in CERT or NRC?

Which has preferable earnings and valuation, CERT or NRC?

Is CERT or NRC more profitable?

Summary

How does National Research compare to GoodRx?

Do institutionals and insiders hold more shares of NRC or GDRX?

Does the media favor NRC or GDRX?

Do analysts rate NRC or GDRX?

Which has higher earnings and valuation, NRC or GDRX?

Is NRC or GDRX more profitable?

Which has more volatility and risk, NRC or GDRX?

Summary

How does National Research compare to Teladoc Health?

Is NRC or TDOC more profitable?

Do analysts recommend NRC or TDOC?

Does the media prefer NRC or TDOC?

Do institutionals & insiders hold more shares of NRC or TDOC?

Which has more volatility and risk, NRC or TDOC?

Which has higher valuation & earnings, NRC or TDOC?

Summary

How does National Research compare to HealthStream?

Is NRC or HSTM a better dividend stock?

Does the media favor NRC or HSTM?

Which has more volatility and risk, NRC or HSTM?

Do analysts rate NRC or HSTM?

Is NRC or HSTM more profitable?

Do insiders & institutionals have more ownership in NRC or HSTM?

Which has better valuation & earnings, NRC or HSTM?

Summary

How does National Research compare to SOPHiA GENETICS?

Is NRC or SOPH more profitable?

Does the media favor NRC or SOPH?

Which has more volatility and risk, NRC or SOPH?

Which has higher earnings & valuation, NRC or SOPH?

Do institutionals & insiders hold more shares of NRC or SOPH?

Do analysts prefer NRC or SOPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRC vs. The Competition

National Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools